newsfilter
← Latest News
GlobeNewswire·

Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026

  • Kamada Ltd. CEO Amir London will present at the Stifel 2026 Healthcare Conference in New York on November 10, 2026, at 10:00 a.m. ET.
  • A live webcast of the Stifel presentation is available via a provided summitcast link.
  • London will attend the Jefferies Global Healthcare Conference in London from November 16-19, 2026, for investor meetings.
  • Kamada is controlled by FIMI Opportunity Funds, which owns approximately 38% of outstanding shares.
  • The company's strategy includes organic growth through six FDA-approved specialty plasma-derived products: KEDRAB, GLASSIA, CYTOGAM, VARIZIG, WINRHO SDF, HEPAGAM B, KAMRAB, & two equine-based anti-snake venoms.
  • Kamada distributes third-party pharmaceuticals in Israel & the MENA region through in-licensing partnerships, including biosimilar launches.
  • The company operates three FDA-approved plasma collection centers in Texas (Beaumont, Houston, San Antonio) to support revenue growth.
  • Kamada aims to secure new mergers, acquisitions, & collaboration opportunities to enhance its product portfolio.